PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
-6.81%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.56B
AUM Growth
+$2.56B
(-1.1%)
Cap. Flow
+$231M
Cap. Flow
% of AUM
9.01%
Top 10 Holdings %
Top 10 Hldgs %
34.93%
Holding
85
New
16
Increased
21
Reduced
12
Closed
9
Top Buys
| 1 |
Merck
MRK
|
$88.6M |
| 2 |
Axsome Therapeutics
AXSM
|
$52.1M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$50M |
| 4 |
Veeva Systems
VEEV
|
$40.1M |
| 5 |
argenx
ARGX
|
$39.7M |
Top Sells
| 1 |
Outset Medical
OM
|
$128M |
| 2 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$34.1M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$28.1M |
| 4 |
Heron Therapeutics
HRTX
|
$20.1M |
| 5 |
HCA Healthcare
HCA
|
$20.1M |
Sector Composition
| 1 | Healthcare | 95.76% |
| 2 | Financials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
AstraZeneca
AZN
$248B
| $38.1M | 1.45% | 576,800 +124,500 | +28% | +$8.23M |
|
27
AbbVie
ABBV
$372B
| $37.7M | 1.44% | +246,235 | New | +$37.7M |
|
28
Cigna
CI
$80.3B
| $37.2M | 1.42% | 141,300 +47,165 | +50% | +$12.4M |
|
29
McKesson
MCK
$85.4B
| $34.5M | 1.32% | 105,811 | – | – |
|
30
Icon
ICLR
$13.8B
| $34.3M | 1.31% | 158,183 | – | – |
|
31
Thermo Fisher Scientific
TMO
$186B
| $33.8M | 1.29% | 62,143 | – | – |
|
32
Cardinal Health
CAH
$35.5B
| $33.4M | 1.28% | 639,783 | – | – |
|
33
Erasca
ERAS
$445M
| $32.8M | 1.25% | 5,881,382 +1,089,976 | +23% | +$6.07M |
|
34
Caribou Biosciences
CRBU
$174M
| $32.6M | 1.24% | 6,000,000 +1,629,455 | +37% | +$8.85M |
|
35
Becton Dickinson
BDX
$55.3B
| $32.2M | 1.23% | 130,697 -26,896 | -17% | -$6.63M |
|
36
Edwards Lifesciences
EW
$47.8B
| $32.2M | 1.23% | 338,155 | – | – |
|
37
Universal Health Services
UHS
$11.6B
| $32M | 1.22% | 317,411 -123,925 | -28% | -$12.5M |
|
|
NVRO
38
DELISTED
NEVRO CORP.
NVRO
| $28.9M | 1.1% | 659,410 +9,897 | +2% | +$434K |
|
39
Tenet Healthcare
THC
$16.3B
| $28.6M | 1.09% | 544,583 | – | – |
|
|
CTLT
40
DELISTED
CATALENT, INC.
CTLT
| $23.4M | 0.89% | 218,366 -37,730 | -15% | -$4.05M |
|
41
BioCryst Pharmaceuticals
BCRX
$1.74B
| $22.9M | 0.87% | +2,162,411 | New | +$22.9M |
|
42
Penumbra
PEN
$10.6B
| $22.8M | 0.87% | 182,786 +16,067 | +10% | +$2M |
|
43
Myriad Genetics
MYGN
$593M
| $21.4M | 0.82% | 1,177,250 -705,107 | -37% | -$12.8M |
|
44
Baxter International
BAX
$12.7B
| $20.8M | 0.79% | +323,907 | New | +$20.8M |
|
45
Elevance Health
ELV
$71.8B
| $20.6M | 0.79% | 42,734 | – | – |
|
46
Generation Bio
GBIO
$40.4M
| $18.2M | 0.69% | 2,773,313 +2,199,035 | +383% | +$14.4M |
|
47
PMV Pharmaceuticals
PMVP
$74.2M
| $17.3M | 0.66% | 1,214,164 +767,864 | +172% | +$10.9M |
|
|
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $16.5M | 0.63% | 130,293 -76,823 | -37% | -$9.72M |
|
|
ADAP
49
Adaptimmune Therapeutics
ADAP
$15.6M
| $15.5M | 0.59% | 9,109,780 +6,735,106 | +284% | +$11.4M |
|
|
VERV
50
DELISTED
Verve Therapeutics
VERV
| $12.9M | 0.49% | 845,186 +475,421 | +129% | +$7.26M |
|